An international peer-reviewed journal for clinical and experimental research in the field of dermatology and venereology.
Published by the Non-Profit Organization Society for Publication of Acta Dermato-Venereologica
The official Journal of:
European Society for Dermatology and Psychiatry
Affiliated with:
International Forum for the Study of Itch
ISI Impact Factor 2018: 3.531 H Index: 75
A new mercaptomix (3.5%), containing 2-mercaptobenzothiazole (MBT) 2.0% instead of 0.5%, has been tested in over 3000 dermatitis patients in 5 Swedish dermatology departments simultaneously with MBT 2.0% and mercaptomix 2.0%. Results showed that mercaptomix 3.5% detected all positive patients and more patch-test positive patients than the other two substances did. The Swedish Contact Dermatitis Research Group will recommend that mercaptomix 3.5% replaces MBT 2.0% and mercaptomix 2.0% in the Swedish baseline series from 2020.
The burden of atopic dermatitis (AD) was assessed in a population-based, cross-sectional questionnaire study among 34,313 Swedish adults. The reported prevalence of AD was 14%. AD, especially when severe, was associated with an increased prevalence of depression, anxiety and a lower academic achievement and occupational status.
